IROX as second-line therapy for metastatic colorectal cancer

被引：0
|
作者：
Alberto Sobrero
机构：
[1] Ospedale San Martino,
来源：
Nature Reviews Clinical Oncology | 2009年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Haller et al. demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer. IROX does not change, but enriches the treatment algorithm of advanced colorectal cancer at the second-line level.
引用
收藏
页码：248 / 250
页数：2
相关论文
共 50 条
  • [41] Second-line dovitinib in metastatic endometrial cancer
    Block, Matthew S.
    Dowdy, Sean C.
    LANCET ONCOLOGY, 2015, 16 (06): : 604 - 606
  • [42] Second-Line Treatment for Metastatic Pancreatic Cancer
    Paluri, Ravi K.
    Kasi, Anup
    Young, Crystal
    Posey, James A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 106 - 115
  • [43] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
    Toshi Takaoka
    Tetsuo Kimura
    Rai Shimoyama
    Shunji Kawamoto
    Kazuki Sakamoto
    Fuminori Goda
    Hiroshi Miyamoto
    Yuji Negoro
    Akihito Tsuji
    Koji Yoshizaki
    Takahiro Goji
    Shinji Kitamura
    Hiromi Yano
    Koichi Okamoto
    Masako Kimura
    Toshiya Okahisa
    Naoki Muguruma
    Yoshiro Niitsu
    Tetsuji Takayama
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 397 - 403
  • [44] Second-line systemic therapy for metastatic colorectal cancer (Russian Translation of Cochrane Plain Language Summary - PLS)
    Mocellin, S.
    Baretta, Z.
    Roqué i Figuls, M.
    Solà, I.
    Martin-Ric-hard, M.
    Hallum, S.
    Bonfill Cosp, X.
    Journal of Nonlinear and Variational Analysis, 2021, 5 (03):
  • [45] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
    Cheng, Ke
    Zhou, Yu-Wen
    Chen, Ye
    Li, Zhi-Ping
    Qiu, Meng
    Liu, Ji-Yan
    CANCER CONTROL, 2022, 29
  • [46] FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
    Giordano Domenico Beretta
    Fausto Petrelli
    Sergio Stinco
    Mary Cabiddu
    Mara Ghilardi
    Michela Squadroni
    Karen Borgonovo
    Sandro Barni
    Medical Oncology, 2013, 30
  • [47] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
    Takaoka, Toshi
    Kimura, Tetsuo
    Shimoyama, Rai
    Kawamoto, Shunji
    Sakamoto, Kazuki
    Goda, Fuminori
    Miyamoto, Hiroshi
    Negoro, Yuji
    Tsuji, Akihito
    Yoshizaki, Koji
    Goji, Takahiro
    Kitamura, Shinji
    Yano, Hiromi
    Okamoto, Koichi
    Kimura, Masako
    Okahisa, Toshiya
    Muguruma, Naoki
    Niitsu, Yoshiro
    Takayama, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 397 - 403
  • [48] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
    Cheng, Ke
    Zhou, Yu-Wen
    Chen, Ye
    Li, Zhi-Ping
    Qiu, Meng
    Liu, Ji-Yan
    CANCER CONTROL, 2022, 29
  • [49] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
    Cheng, Ke
    Zhou, Yu-Wen
    Chen, Ye
    Li, Zhi-Ping
    Qiu, Meng
    Liu, Ji-Yan
    CANCER CONTROL, 2022, 29
  • [50] The role of second-line chemotherapy in colorectal cancer
    Schmoll, HJ
    Buchele, T
    Schober, C
    ONKOLOGIE, 1997, 20 (04): : 288 - 294
12345